■唑来膦酸可以抑制破骨细胞的活性,因此,可以减缓或抑制骨质流失。目的系统评价唑来膦酸治疗骨质疏松症的疗效和安全性。
■四个数据库,PubMed,Embase,科克伦图书馆,和WebofScience,在2022年12月26日之前进行了系统搜索。主要结果包括骨矿物质密度(BMD),1型胶原(CTX)的羧基末端交联端肽,骨特异性碱性磷酸酶(BSAP),1型前胶原N末端肽(P1NP),不良事件,和骨折。次要结果包括血清硬化蛋白水平,视觉模拟评分(VAS)评分,和Oswestry残疾指数(ODI)。
■本荟萃分析共纳入22项随机对照试验。Meta分析结果显示,唑来膦酸可有效提高腰椎骨密度,股骨颈,转子和血清硬化蛋白水平;CTX降低,BSAP,P1NP,VAS评分,骨质疏松症患者的ODI。关于安全,唑来膦酸可降低骨折发生率,但不良反应相对较多.
■唑来膦酸可以显着提高腰椎的BMD,股骨颈和转子,有效降低骨质疏松患者骨折发生率,从而显著提高患者的生活质量。然而,不良事件发生率高于安慰剂组.
UNASSIGNED: Zoledronic acid can inhibit the activity of osteoclasts, and thus, may slow or inhibit bone loss. The purpose of this study was to systematically evaluate the efficacy and safety of zoledronic acid in the treatment of osteoporosis.
UNASSIGNED: Four databases, PubMed, Embase, Cochrane Library, and Web of Science, were systematically searched up to December 26, 2022. The primary outcomes included bone mineral density (BMD), carboxy-terminal cross-linked telopeptide of type 1 collagen (CTX), bone-specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal prope-ptide (P1NP), adverse events, and fracture. Secondary outcomes included serum sclerostin level, Visual Analogue Scale (VAS) score, and Oswestry Disability Index (ODI).
UNASSIGNED: A total of 22 randomized controlled trials were included in this meta-analysis. Meta-analysis results showed that zoledronic acid was effective in increasing BMD of the lumbar spine, femoral neck, trochanter and serum sclerostin level; and reduced CTX, BSAP, P1NP, VAS score, and ODI in patients with osteoporosis. Regarding safety, zoledronic acid could reduce the incidence of fractures but had relatively more adverse events.
UNASSIGNED: Zoledronic acid can significantly improve BMD of the lumbar spine, femoral neck and trochanter, and effectively reduce incidence of fracture in patients with osteoporosis, thereby significantly improving patients\' quality of life. However, the incidence of adverse events was higher than that of patients treated with placebo.